Skip to main content
×
Home

Canadian Headache Society Guideline for Migraine Prophylaxis: Supplement 2

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Canadian Headache Society Guideline for Migraine Prophylaxis: Supplement 2
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Canadian Headache Society Guideline for Migraine Prophylaxis: Supplement 2
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Canadian Headache Society Guideline for Migraine Prophylaxis: Supplement 2
      Available formats
      ×
Abstract
Copyright
References
Hide All
1Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF.A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992 Aug;19(3):3339.
2O’Brien B, Goeree R, Streiner D.Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol. 1994 Oct; 23(5):10206.
3Cooke LJ, Becker WJ.Migraine prevalence, treatment and impact: the Canadian women and migraine study. Can J Neurol Sci. 2010; 37:5807.
4Leonardi M, Steiner T, Scher A, Lipton RB.The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain. 2005;6:42940.
5Zeeberg P, Olesen J, Jensen R.Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006;66:18948.
6Headache Classification Subcommittee of the International Headache Society The International Classification of headache disorders. Cephalalgia. 2004;24(Suppl 1):9160.
7Jelinski SE, Becker WJ, Christie SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:57888.
8Silberstein SD and the US Headache Consortium. Pracitce Parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000;55:75462.
9Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ. 1997;156: 127387.
10Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF and the AMPP Advisory Group. Migraine Prevalence, disease burden, and the need for preventative therapy. Neurology. 2007; 68:3439.
11Mathew N, Saper J, Silberstein S, Rankin L, Markley H.Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):2816.
12Klapper J.Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:1038.
13Brandes JL, Saper JR, Diamond M, et al.Topiramate for Migraine Prevention. JAMA. 2004;291:96573.
14Jensen R, Brinck T, Olesen J.Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:64751.
15Diener HC, Agosti R, Allais G, Bergmans P, bussoni G, Davies B, Ertas M, for the TOPMAT- MIG 303 Investigator Group. Cessation versus continuation of 6-month migraine preventative therapy with topiramate (PROMPT): a randomised, double-blind placebo-controlled trial. Lancet Neurol. 2007;6:105462.
16Becker WJ, Christie SN, Ledoux S, Binder C.Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache. 2006;46:142430.
17Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J.Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol. 1993;50: 82530.
18Woeber C, Woeber-Bingol C, Koch G, Wessely P.Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991;11:2516.
19Sorensen PS, Hansen K, Olesen J.A placebo-contolled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:714.
20Members of the Task Force: Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS.EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16:96881.
21Diener H-C, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT - MIG 201 (TOP- Chrome) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:8142.
22Mei D, Ferraro D, Zelano G, et al.Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006;29:26975.
23Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30: 793803.
24Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:80414.
25Hagen K, Albretsen C, Vilming ST, et al.Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29:22132.
26Katsarava Z, Schneeweiss S, Kurth Tet al.Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:78890.
27Limmroth V, Biondi D, Pfeil J, Schwalen S.Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache. 2007;47:1321.
28Lipton RB, Silberstein S, Dodick D, et al.Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31:1830.
29Headache Classification Subcommittee of the International Headache Society. The International Classification of headache disorders. Cephalalgia. 2004;24 Suppl 1:9160.
30Ad Hoc Committee on Classification of Headache. JAMA. 1962;179:71718.
31Pringsheim T, Davenport WJ, Becker WJ.Prophylaxis of migraine headache. CMAJ. 2010;182:67985.
32Harris RD, Helfand M, Woolf SH, et al.Current methods of the US preventive services task force. Areview of the process. Am J Prev Med. 2001;20(3S):2135.
33Guyatt GH, Oxman AD, Vist GE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336;9246.
34Guyatt GH, Oxman AD, Kunz R, et al.What is “quality of evidence” and why is it important to clinicians? BMJ. 2008 May 3;336(7651):9958.
35Balshem H, Helfand M, Schuenemann HJ, et al.GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:4016.
36Cuello García CA, Pacheco Alvarado KP, Pérez Gaxiola G. Grading recommendations in clinical practice guidelines: randomised experimental evaluation of four different systems. Arch Dis Child. 2011 May 19.
37Brożek JL, Akl EA, Compalati E, et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011 May;66(5):58895.
38Mathew N, Saper J, Silberstein S, Rankin L, Markley H.Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):2816.
39Klapper J.Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:1038.
40Freitag FG, Collins SD, Carlson HA, et al.A randomized trial of divalproex sodium extended release tablets in migraine prophylaxis. Neurology. 2002;58:16529.
41Hering R, Kuritzky A.Sodium valproate in the prophylactic treatment of migraine: a double blind study versus placebo. Cephalalgia. 1992;12:814.
42Jensen R, Brinck T, Olesen J.Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:64751.
43DiTrapani B, Mei D, Marra C, Capuano A.Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo controlled study. Clin Ter. 2000;151:1458.
44Mathew N, Rapoport A, Saper J, et al.Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:11928.
45Brandes JL, Saper JR, Diamond M, et al.Topiramate for Migraine Prevention. JAMA. 2004;291:96573.
46Silberstein S, Neto W, Schmitt J, Jacobs D.Topiramate in migraine prevention. Arch Neurol. 2004;61:4905.
47Diener H, Tfelt-Hansen P, Dahlof C, et al.Topiramate in migraine prophylaxis. J Neurol. 2004;251:94350.
48Mei D, Capuano A, Vollono C, et al.Topiramate in migraine prophylaxis: a randomized double blind versus placebo study. Neurol Sci. 2004;25:24550.
49Silberstein S, Hulihan J, Karim R, et al.Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo controlled, double blind, 12-week pilot study. Clin Ther. 2006;28(7):100211.
50Storey JR, Calder CS, Hart DE, Potter DL.Topiramate in Migraine Prevention: A double blind, placebo-controlled study. Headache. 2001;41:96875.
51Shaygannejad V, Janghorbani M, Ghorbani A, Ashtari F, Zakizade N, Nasr V.Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46:6428.
52Gupta P, Singh S, Goyal V, Shukla B, Behari M.Low dose topiramate versus lamotrigine in migraine prophylaxis (the lotolamp study). Headache. 2007;47:40212.
53Dodick DW, Freitag F, Banks J, et al.Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009 Mar;31(3):54259.
54Keskinbora K, Aydinli I.A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008 Dec;110 (10):97984.
55Ashtari F, Shaygannejad V, Akbari M.A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008 Nov;118(5):3015.
56Lipton RB, Silberstein S, Dodick D, et al.Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011 Jan;31(1):1830.
57Lo YL, Lum SY, Fook-Chong S, et al.A pilot study of topiramate dosages for migraine prophylaxis in an Asian population. J Headache Pain. 2010 Apr;11(2):1758.
58Millán-Guerrero RO, Isais-Millán R, Barreto-Vizcaíno S, et al.Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol. 2008;59(5):23742.
59Gomersall JD, Stuart A.Amitriptyline in migraine prophylaxis. J Neurol Neurosurg Psychiatry. 1973;36:68490.
60Ziegler DK, Hurwitz A, Hassanein RS.Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:4869.
61Bank J.A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994;34:4768.
62Couch JR, Hassanein RS.Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36:6959.
63Jackson JL, Shimeall W, Sessums L, et al.Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:c5222 doi:10.1136/bmj.c5222.
64Ozyalcin S, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R.The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:14452.
65Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B.Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:448.
66Linde K, Rossnagel K.Propranolol for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.:CD003225.DOI:10.1002/14651858.CD003225.pub2.
67Freitag FG, Diamond S.Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc. 1984;84(4):3437.
68Ryan RE, Ryan RE, Sudilovsky A.Nadolol and placebo comparison study in the prophylactic treatment of migraine. Panminerva Med. 1982;24(2):8994.
69Sorensen PS, Hansen K, Olesen J.A placebo-contolled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:714.
70Frenken CW, Nuijten ST.Flunarizine, a new preventive approach to migraine. Clin Neurol Neurosurg. 1984:86(1):1720.
71Mendenopoulos G, Manafi TH, Logothetis I, Bostantjopoulos S.Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia. 1985;5:317.
72Louis P.A double blind placebo-controlled prophylactic study of flunarizine in migraine. Headache. 1981;21:2359.
73Al Deeb SM, Biary N, Bahou Y, Al Jaberi M, Khoja W.Flunarizine in migraine: a double blind placebo-controlled study (in a Saudi population). Headache. 1992;32:4612.
74Thomas M, Behari M, Ahuja GK.Flunarizine in migraine prophylaxis: an Indian trial. Headache. 1991;31:61315.
75Cerbo R, Casacchia M, Formisano R, et al.Flunarizine-pizotifen single dose double blind crossover trial in migraine prophylaxis. Cephalalgia. 1986;6:1518.
76Rascol A, Montastruc JL, Rascol O.Flunarizine versus pizotifen: a double blind study in the prophylaxis of migraine. Headache. 1986;26:835.
77Louis P, Spierlings EL.Comparison of flunarizine and pizotifen in migraine treatment: a double blind study. Cephalalgia. 1982;2:197203.
78Markley HG, Cheronis J, Piepho RW.Verapamil in prophylactic therapy of migraine. Neurology. 1984;34:9736.
79Soloman GD, Steel JG, Spaccavento LJ.Verapamil prophylaxis of migraine. JAMA. 1983;250:25002.
80Schrader H, Stovner LJ, Helde G, Sand T, Bovim G.Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BMJ. 2001;322:15.
81Tronvik E, Stovner LJ, Helde G, Sand T, Bovin G.Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA. 2003;289:659.
82Diener HC, Gendolla A, Feuersenger A, et al.Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009 Sep;29(9):9217.
83Schoenen J, Jacquy J, Lenaerts M.Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology. 1998;50(2):46670.
84Maizels M, Blumenfeld A, Burchette R.A combination of riboflavin, magnesium, and feverfew in migraine prophylaxis: a randomized trial. Headache. 2004;44:88590.
85Sandor P, Di Clemente L, Coppola G, et al.Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized, controlled trial. Neurology. 2005;64:71315.
86Peikert A, Wilimzig C, Kohne-Volland R.Prophylaxis of migraine with oral magnesium: results from a prospective, multicentre, placebo-controlled and double blind randomized study. Cephalalgia. 1996;16:25763.
87Pfaffenrath V, Wessely P, Meyer C, et al.Magnesium in the prophylaxis of migraine- a double blind, placebo controlled study. Cephalalgia. 1996;16:43640.
88Köseoglu E, Talaslioglu A, Gönül AS, M Kula. The effects of magnesium prophylaxis in migraine without aura. Magnes Res. 2008 Jun;21(2):1018.
89Lipton RB, Gobel K, Einhaupl KM, Wilks K, Mauskop A.Petasites hybridus root (butterbur) is an effective preventative treatment for migraine. Neurology. 2004;63:22404.
90Diener H, Rahlfs VW, Danesch U.The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51:8997.
91Pfaffenrath V, Diener H, Fischer M, Friede M, Henneicke-von Zepelin. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis- a double blind, multicentre, randomized placebo controlled dose-response study. Cephalalgia. 2002;22:52332.
92Murphy JJ, Heptinstall S, Mitchell JR.Randomised double blind placebo controlled trial of feverfew in migraine prevention. Lancet. 1988;8604:18992.
93Diener H, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg TID feverfew CO2 extract (MIG-99) in migraine prevention- a randomized, double-blind, multicentre, placebo controlled study. Cephalalgia. 2005;25:103141.
94DeWeerdt CJ, Bootsma HPR, Hendriks H.Herbal medicines in migraine prevention. Phytomedicine. 1996;3(3):22530.
95Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A.Botulinum toxin A in the prophylactic treatment of migraine- a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:83843.
96Saper J, Mathew N, Loder E, DeGryse R, VanDenburgh AM.A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med. 2007;8(6):47885.
97Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C.A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007;27:492503.
98Vo AH, Satori R, Jabbari B, et al.Botulinum toxin type-A in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med. 2007;78(5):B11318.
99Aurora SK, Gawel M, Brandes JL, Pokta S, Van Denburgh AM.Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized double blind placebo controlled exploratory study. Headache. 2007;47:48699.
100Elkind AH, O’Carroll P, Blumenfeld A, DeGryse R, Dimitrova R.A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006;7(10):68896.
101Silberstein S, Mathew N, Saper J, Jenkins S.Botulinum toxin type A as a migraine preventative treatment. Headache. 2000;40:44550.
102Anand KS, Prasad A, Singh MM, Sharma S, Bala K.Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther. 2006;13:1837.
103Blumenfeld AM, Schim JD, Chippendale TJ.Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008 Feb;48(2):21020.
104Cady R, Schreiber C.Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008 Jun;48(6):90013.
105Petri S, Tölle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A; Dysport Migraine Study Group. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. Eur Neurol. 2009;62(4):20411.
106Chankrachang S, Arayawichanont A, Poungvarin N, et al.Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. Headache. 2011 Jan;51(12):5263.
107Shuhendler AJ, Lee S, Siu M, et al.Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy. 2009 Jul;29(7):78491.
108Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 Jul;30(7):793803.
109Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 Jul;30(7):80414.
110Bellevance AJ, Meloche JR.A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache. 1990;30:71015.
111Osterman PO.A comparison between placebo, pizotifen and divascan in migraine prophylaxis. Acta Neurologica Scandinavica. 1977;56:1728.
112Sjaastad O, Stensrud P.Appraisal of BC-105 in migraine prophylaxis. Acta Neurologica Scandinavica. 1969;45:594600.
113Lawrence ER, Hossain M, Littlestone W.Sanomigran for migraine prophylaxis; controlled multicentre trial in general practice. Headache. 1977;17:10912.
114Carroll JD, Maclay WP.Pizotifen (BC-105) in migraine prophylaxis. Curr Med Res Opin. 1975:3(2): 6871.
115Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline (Guideline 107). Available at http://www.sign.ac.uk.
116Koch HJ, Jurgens TP.Antidepressants in long-term migraine prevention. Drugs. 2009;69:119.
117Members of the Task Force: Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS.EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009 16:96881.
118Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J.Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008 Feb 12;70(7):54855.
119Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI.Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010 Oct 26;75(2):152732.
120Hagen K, Albretsen C, Vilming ST, et al.Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009;29:22132.
121Diener H-C, Dodick DW, Goadsby PJ, et al.Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29:10217.
122Peres MF, Silberstein S, Moreira F, et al.Patients’ preference for migraine preventative therapy. Headache. 2007;47:5405.
123Kowacs PA, Piovesan EJ, Tepper SJ.Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009;49:10227.
124Members of the Task Force: Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS.EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Euro J Neurol. 2009;16:96881.
125Dodick DW, Freitag F, Banks J, et al, Capss-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group non-inferiority trial in adult migraineurs. Clin Ther. 2009;31:54259.
126Koch HJ, Jurgens TP.Antidepressants in long-term migraine prevention. Drugs. 2009;69:119.
127Bigal ME, Lipton RB, Biondi J, Xiang J, Hulihan J.Weight change and clinical markers of cardiovascular disease risk during preventative treatment of migraine. Cephalalgia. 2009;29:118896.
128Jette N, Patten S, Williams J, Becker W, Wiebe S.Comorbidity of migraine and psychiatric disorders-a national population-based study. Headache. 2008 Apr;48(4):50116.
129Jelinski SE, Magnusson JE, Becker WJ; CHORD Study Group. Factors associated with depression in patients referred to headache specialists. Neurology. 2007 Feb 13;68(7):48995.
130Hamelsky SW, Lipton RB.Psychiatric comorbidity of migraine. Headache. 2006 Oct;46(9):132733.
131Lam RW, Kennedy SH, Grigoriadis S, et al.Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IIIx. PharmacotherapyJ Affect Disord. J Affect Disord. 2009 Oct;117 Suppl 1:S2643.
132Pringsheim T, Davenport WJ, Becker WJ.Prophylaxis of migraine headache. CMAJ. 2010 Apr 20;182(7):26976.
133Guaiana G, Barbui C, Hotopf M.Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2003;(2):CD004186. Review.
134Jelinski SE, Becker WJ, Christie SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:57888.
135Watson CP, Vernich L, Chipman M, Reed K.Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998 Oct;51(4):116671.
136Swinson RP and the Working Group. Clinical Practice Guidelines: Management of anxiety disorders. Can J Psychiat. 2006;51 (Suppl 2): 1S90.
137Davidson JR, Feltner DE, Dugar A.Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiatry. 2010;12(2). pii: PCC. 09r00772.
138Silberstein SD, Dodick D, Freitag F, et al.Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr;47(4):58599.
139Mula M, Sander JW.Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30:55567.
140Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM: B-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002; 288:3517.
141Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R.The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 1996 Jul;49(7):80915.
142Gillman PK.Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Brit J Pharmacol. 2007;151:73748.
143Cipriani A, Furukawa TA, Salanti G, et al.Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Feb 28;373(9665):74658.
144Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline (Guideline 107). Available at http://www.sign.ac.uk.
145Schulman EA, Lake AE III, Goadsby PJ, et al.Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48:77882.
146Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ.Why headache treatment fails. Neurology. 2003;60:106470.
147Evans RW, Pascual J, Lainez MJA, Leira R.Bending the Rule of Monotherapy for Migraine Prevention? Headache. 2005;45:74850.
148Peterlin BL, Calhoun AH, Siegel S, Mathew NT.Rational Combination Therapy in Refractory Migraine. Headache. 2008;48:80519.
149Pascual J, Rivas MT, Leira R.Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007:115:81-3.
150Martínez HR, Londoño O, Cantú-Martínez L, del Carmen Tarín L, Castillo CD.Topiramate as an adjunctive treatment in migraine prophylaxis. Headache. 2003 Nov-Dec;43(10):10804.
151Pascual J, Leira R, Láinez JM.Combined therapy for migraine prevention? Clinical experience with a b-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23:9612.
152Keskinbora K, Aydinli I.Adouble-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110:97984.
153Fox AW, Diamond ML, Spierings ELH.Migraine during pregnancy. CNS Drugs. 2005;19(6):46581.
154Menon R, Bushnell CD.Headache and pregnancy. Neurologist. 2008;14:10819.
155Silberstein SD.Headaches in pregnancy. J Headache Pain. 2005 Sep;6(4):1724.
156Goadsby PJ, Goldberg J, Silberstein SD.Migraine in pregnancy. BMJ. 2008;336:15024.
157Pfaffenrath V, Rehm M.Migraine in pregnancy. Drug Safety. 1998 Nov;19(5):3838.
158Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM; APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine (2010), Acute Pain Management: Scientific Evidence (3rd edition), ANZCA & FPM, Melbourne.
159Payne J L, Meltzer-Brody S.Antidepressant Use During Pregnancy: Current Controversies and Treatment Strategies. Clin Obstet Gynecol. 2009;52(3):46982.
160Nulman I, Rovet J, Stewart DE, et al.Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002 Nov;159(11):188995.
161Nulman I, Rovet J, Stewart DE, et al.Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997 Jan 23;336(4): 25862.
162MacGregor EA.Migraine in pregnancy and lactation: a clinical review. J Fam Plann Reprod Health Care. 2007;33(2):8393.
163Beaton K.Health professional letter, Drug information. Janssen-Ortho. May 31, 2010.
164Lucas S.Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep. 2009 Oct; 13(5):3928.
165Ito S.Drug therapy for breast-feeding women. N Engl J Med. 2000; 343(2):11826.
166Lanza di Scalea T, Wisner KL.Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009; 52(3):48397.
167Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001; 108:77689.
168Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ. 1997;156:127387.
169Evans RW, Bigal ME.Grosberg B, Lipton RB.Target doses and titration schedules for migraine preventive medications. Headache. 2006;46:1604.
170Purdy RA.Headache in adults. In: Gray J, editor. Therapeutic choices. 5th ed. Ottawa: Canadian Pharmacists Association; 2007. p. 16985.
171Jellin JM, Gregory PJ, et al.Pharmacist’s letter/prescriber’s letter natural medicines comprehensive database. 10th ed. Stockton, CA: Therapeutic Research Faculty; 2008.
172Briggs GG, Freeman RK, Yaffe SJ.Drugs in pregnancy and lactation. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
173Repchinsky C, editor-in-chief. The compendium of pharmaceuticals and specialties. The Canadian drug reference for health professionals. Ottawa: Canadian Pharmacists Association; 2009.
174Sauro KM, Becker WJ.Multidisciplinary treatment for headache in the Canadian healthcare setting. Can J Neurol Sci. 2008 Mar;35(1):4656.
175Sauro KM, Becker WJ.The stress and migraine interaction. Headache. 2009 Oct;49(9):137886.
176Wöber C, Holzhammer J, Zeitlhofer J, Wessely P, Wöber-Bingöl C.Trigger factors of migraine and tension-type headache: experience and knowledge of the patients. Headache Pain. 2006 Sep;7(4):18895.
177Martin PR.Behavioral Management of Migraine Headache Triggers: Learning to Cope with Triggers. Curr Pain Headache Rep. 2010;14:2217.
178Kelman L.The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394402.
179Robbins L.Precipitating factors in migraine: a retrospective review of 494 patients. Headache. 1994;34:2146.
180Alpay K, Ertas M, Orhan EK, Ustay DK, Lieners C, Baykan B.Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia. 2010 Jul;30(7):82937.
181Pascual J, Oterino A.IgG-mediated allergy: a new mechanism for migraine attacks? Cephalalgia. 2010 Jul;30(7):7779.
182Sun-Edelstein C, Mauskop A.Foods and supplements in the management of migraine headaches. Clin J Pain. 2009 Jun;25(5):44652.
183Calhoun AH, Ford S.Behavioral sleep modifications may revert transformed migraine to episodic migraine. Headache. 2007;45:117883.
184Borkum JM.Chronic headaches: Biology, psychology, and behavioral treatment. Lawrence Erlbaum Associates, Publishers, Mahwah, New Jersey 2007.
185Rains JC, Penzien DB, McCrory DC, Gray RN.Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache. 2005;45 Suppl 2:S92109.
186Campbell JK, Penzien DB, Wall EM.Evidenced-Based Guidelines For Migraine Headache: Behavioral and Physical Treatments. http://www.aan.com/professionals/practice/pdfs/gl0089.pdf
187Silberstein SD and the US Headache Consortium. Practice Parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000;55:75462.
188Pryse-Phillips WE, Dodick DW, Edmeads JG, et al.Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ. 1998 Jul 14;159(1):4754.
189Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline (Guideline 107). Available at http://www.sign.ac.uk.
190Penzien DB, Rains JC, Andrasik F.Behavioral management of recurrent headache: Three decades of experience and empiricism. Appl Psychophysiol Biofeedback. 2002 Jun;27(2):16381.
191Dittrich SM, Günther V, Franz G, Burtscher M, Holzner B, Kopp M.Aerobic exercise with relaxation: influence on pain and psychological well-being in female migraine patients. Clin J Sport Med. 2008 Jul;18(4):3635.
192Lemstra M, Stewart B, Olszynski WP.Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache. 2002;42:84554.
193Magnusson JE, Riess CM, Becker WJ.Effectiveness of a multidisciplinary treatment program for chronic daily headache. Can J Neurol Sci. 2004 Feb;31(1):729.
194Gunreben-Stempfle B, Griessinger N, Lang E, Muehlhans B, Sittl R, Ulrich K.Effectiveness of an intensive multidisciplinary headache treatment program. Headache. 2009 Jul;49(7):9901000.
195Holroyd KA, Cottrell CK, O’Donnell FJ, et al.Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010 Sep 29;341:c4871. doi: 10.1136/bmj.c4871.
196AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12:1823.
197Peres MF, Silberstein S, Moreira F, et al.Patients’ preference for migraine preventative therapy. Headache. 2007;47:5405.
198Kowacs PA, Piovesan EJ, Tepper SJ.Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009;49:10227.
199Becker WJ, Gladstone JP, Aubé M.Migraine prevalence, diagnosis, and disability. Can J Neurol Sci. 2007;34:S39.
200Becker WJ, Gawel M, Mackie G, South V, Christie SN. Migraine treatment. Can J Neurol Sci. 2007;34:S1019.
201Becker WJ, Giammarco R, Wiebe V.Moving forward to improve migraine management in Canada. Can J Neurol Sci. 2007;34:S206.
202Headache Classification Subcommittee of the International Headache Society The International Classification of headache disorders. Cephalalgia. 2004;24(Suppl 1):1160.
203Ad Hoc Committee on Classification of Headache. CMAJ. 1962;179:71718.
204Guyatt GH, Oxman AD, Vist GE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336;9246.
205Guyatt GH, Oxman AD, Kunz Ret al.What is “quality of evidence” and why is it important to clinicians? BMJ. 2008 May 3;336(7651):9958.
206Sauro KM, Rose MS, Becker WJ, et al.HIT-6 and MIDAS as Measures of Headache Disability in a Headache Referral Population. Headache. 2010 Mar;50(3):38395.
207Silberstein SD, Winner PK, Chmiel JJ.Migraine preventive medication reduces resource utilization. Headache. 2003;43(3):1718.
208Etemad LR, Yang W, Globe D, Barlev A, Johnson KA.Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):13744.
209Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ.Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache. 2007;47:50010.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Neurological Sciences
  • ISSN: 0317-1671
  • EISSN: 2057-0155
  • URL: /core/journals/canadian-journal-of-neurological-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 733 *
Loading metrics...

Abstract views

Total abstract views: 537 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 18th November 2017. This data will be updated every 24 hours.